Key Highlights
- BioStem Technologies (NASDAQ:BSEM) closed at USD 1.25 on Tuesday, November 10, 2026, up 12.05% from a calculated prior close of USD 1.12, among the gainers in a published screener snapshot of 4,625 names.
- Volume was 146,690 shares, a relative Volume of 0.70, worth about USD 183,363 at the close (calculated); third-quarter results and a 4:30 p.m. ET call are scheduled for November 12, 2026.
- First-half 2026 Revenue fell to USD 14.0 million from USD 26.9 million, the net loss was USD 17.8 million, and cash was USD 6.96 million at June 30, 2026 against USD 29.5 million at year end.
- The snapshot shows a Market Value of USD 23.43 million, trailing diluted EPS of USD -1.68, EPS growth of -247.05%, no P/E and a Dividend Yield of 0.00%.
What Moved BioStem Technologies on November 10 (+12.05%)
Shares of the regenerative medicine company ended the regular session at USD 1.25, up 12.05%. Simple arithmetic gives a calculated prior close of about USD 1.12 on Monday, November 9, 2026, a gain of roughly USD 0.13 per share. The shares remain about 62.7% below the USD 3.35 price of the May 21, 2026 private Placement and about 3.1% below the USD 1.29 close of October 29, 2026 (calculated). Volume of 146,690 shares at a relative volume of 0.70 means turnover was about 30% below its recent average. The company set its third-quarter results release and conference call for Thursday, November 12, 2026, two days after the move.
The Rationale: No Catalyst Identified Before the November 12 Results
No catalyst identified in published coverage for November 9 or 10, 2026. The most recent company item found is the October 2026 announcement of the third-quarter call. The latest filed numbers are from the Form 10-Q for the period ended June 30, 2026, filed on August 12, 2026: Q2 revenue of USD 7.9 million, a Q2 net loss of USD 9.0 million, and operating cash outflow of USD 6.4 million in the first half. The company holds FDA 510(k) clearance dated June 5, 2026 for the Catalyze product and owes USD 10.0 million in contingent consideration to the seller, of which USD 500,000 was paid on July 6, 2026. As general context, shares often move ahead of an Earnings date as traders position, and small caps can bounce after weakness. These are general mechanisms, not confirmed causes.
Valuation, Liquidity and Risks for BioStem Technologies
The snapshot market value of USD 23.43 million implies about 18.7 million shares at USD 1.25 (calculated), close to the 17,849,471 shares on the August 12, 2026 cover page. Trailing EPS of USD -1.68 and EPS growth of -247.05% mean there is no P/E and no dividend. Cash of USD 6.96 million compares with USD 21.2 million of total liabilities, a USD 1.0 million secured note due April 23, 2027, and a Going Concern warning in the 10-Q. The company has no numeric guidance and expects net losses for at least 12 months. A published estimate put liquidity near USD 7 million against a monthly burn near USD 3 million, which raises dilution risk. With 146,690 shares traded, a small number of trades can move the price. Nothing here implies the gain will continue.
Where Things Stand
BioStem Technologies (NASDAQ:BSEM) rose 12.05% to USD 1.25 on November 10, 2026, but no catalyst was identified in published coverage; the likeliest context is positioning ahead of the November 12 third-quarter results. Volume was 146,690 shares at a relative volume of 0.70, the market value is USD 23.43 million, cash was USD 6.96 million at June 30 and the filing carries a going concern warning.






Please wait processing your request...